ASCO 2023 | The promise of pomalidomide-backbone combinations for R/R multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses therapy combinations for relapsed/refractory (R/R) multiple myeloma, emphasizing the importance of defining optimal sequencing strategies. Dr. Cerchione provides insight into drug combinations like lenalidomide, bortezomib, and dexamethasone (RVD) and pomalidomide, bortezomib, and dexamethasone (PVd) as well as the utilization of pomalidomide and its synergistic effects with other drugs. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
